Candida species remain a significant cause of nosocomial bloodstream infections, associated with prolonged
hospital stay in the ICU and high healthcare cost. The incidence of Candida is very high in certain risk groups of patients
(AIDS, diabetes, cancer, etc.). Recent developments of nanotechnology have strongly contributed to the design
of new multifunctional drug carriers that improve drug bioavailability through a controlled and prolonged release profile
or even through a more specific targeted delivery of the antifungal agent. Those types of systems have strongly
increased with a progressive generation of new structures, permitting the conjunction of new materials, biomolecules,
physical and chemical techniques, for better outcomes. Nanotechnology shows expanded possibilities within the medical
field and in the case of the yeast infections it may overcome several issues related with the fungal proliferation or
higher inhibition of the pathogen causing the infection. This review covers a period of the most representative research
of Candidiasis since 1993 to the present.
Keywords: Fungal infections, candidiasis, encapsulation, antifungal agents, nanoparticles, mucoadhesion.
Rights & PermissionsPrintExport